InsidersTradesSigma
Track the PARADIGM BIOPHARMACEUTICALS LIMITED.. share price and the full directors' dealings record of the company, a publicly traded company based in Australia. Shares trade on AU AU, under the supervision of ASX. Market capitalisation: €102.3m. The latest transaction was disclosed on 18 June 2026 (Other). Among the most active insiders: Unknown. Every trade is openly available.
Analysts rate PARADIGM BIOPHARMACEUTICALS LIMITED.. Strong Buy (bullish), based on 2 analysts. Average price target: A$1.37.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
PARADIGM BIOPHARMACEUTICALS LIMITED is an Australian Securities Exchange listed company focused on developing treatments for chronic diseases and musculoskeletal disorders. It specializes in regenerative medicine and stem cell-based therapies.